Valuation: Kodiak Sciences Inc.

Market Cap 2.52B 2.21B 2.06B 1.89B 3.54B 240B 3.61B 24.39B 9.55B 119B 9.44B 9.24B 412B P/E 2026 *
-10.8x
P/E 2027 * -12.9x
Enterprise Value 2.33B 2.05B 1.91B 1.75B 3.28B 223B 3.34B 22.6B 8.85B 110B 8.75B 8.56B 382B EV / Sales 2026 *
-
EV / Sales 2027 * 49.3x
Free-Float
94.82%
Yield 2026 *
-
Yield 2027 * -
1 day-3.87%
1 week-5.02%
Current month+3.41%
1 month+12.10%
3 months-11.31%
6 months+54.55%
Current year+44.10%
1 week 38.86
Extreme 38.86
43
1 month 35.77
Extreme 35.77
44.85
Current year 20.88
Extreme 20.88
47.84
1 year 6.21
Extreme 6.2103
47.84
3 years 1.37
Extreme 1.37
47.84
5 years 1.37
Extreme 1.37
131.97
10 years 1.37
Extreme 1.37
171.21
Manager TitleAgeSince
Chief Executive Officer 53 2008-12-31
Director of Finance/CFO 64 2015-12-31
Chief Tech/Sci/R&D Officer - 2023-12-31
Director TitleAgeSince
Chairman 53 2008-12-31
Director/Board Member 57 2015-08-31
Director/Board Member 55 2018-07-17
Date Insider Type Main position Quantity % Market Cap.
7/15/26 Free

Chief Financial Officer

66,500 0.1063%
7/15/26 Free

Chief Executive Officer

100,000 0.1598%
6/30/26 Free

Director

17,731 0.0283%
Change 5-day change 1-year change 3-year change Capi.($)
-3.87%-5.02%+388.96%+1,303.83% 2.62B
-2.25%+1.55%+50.84%+70.04% 56.19B
-1.32%-2.71%+34.27%+77.57% 54.83B
+1.49%+0.13%-18.03%-13.94% 23.04B
-0.57%-4.13%+2.34%+387.73% 22.7B
+1.97%+1.29%+17.08%-10.79% 20.23B
0.00%+3.00%+27.41%-29.52% 17.83B
-5.84%-7.39%+21.46%+533.75% 15.65B
-6.69%-5.11%+169.13%+304.89% 15.24B
+1.25%+0.69%+27.30%+184.69% 14.03B
Average -1.58%-0.66%+72.08%+280.83% 24.23B
Weighted average by Cap. -1.33%-0.27%+39.29%+144.12%

Financials

2026 *2027 *
Net sales - 45.92M 40.3M 37.53M 34.52M 64.7M 4.39B 65.81M 445M 174M 2.18B 172M 169M 7.52B
Net income -241M -211M -197M -181M -339M -23B -345M -2.33B -913M -11.4B -904M -884M -39.4B -221M -194M -181M -166M -312M -21.13B -317M -2.14B -839M -10.48B -830M -812M -36.2B
Net Debt -184M -162M -151M -139M -260M -17.61B -264M -1.79B -700M -8.73B -692M -677M -30.17B -252M -221M -206M -189M -355M -24.08B -361M -2.44B -957M -11.94B -946M -926M -41.27B
Logo Kodiak Sciences Inc.
Kodiak Sciences Inc. is a precommercial retina-focused biotechnology company. The Company is developing a portfolio of three late-stage clinical programs. Zenkuda (tarcocimab tedromer) has a BLA-ready profile in diabetic retinopathy, retinal vein occlusion and wet AMD, and, together with KSI-501, is being explored in the BLA-facing Phase 3 DAYBREAK wet AMD study. KSI-101 is a bispecific protein being explored in two BLA-facing Phase 3 studies in Macular Edema Secondary to Inflammation (MESI). Its Antibody Biopolymer Conjugate (ABC) Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its second investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high prevalence retinal vascular diseases to address the leading unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy.
Employees
130
Date Price Change Volume
26-07-28 US$40.29 -3.87% 754,805
26-07-27 US$41.91 +1.21% 464,832
26-07-24 US$41.41 +0.95% 512,906
26-07-23 US$41.02 -2.15% 387,196
26-07-22 US$41.92 -1.18% 435,388
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
40.29USD
Average target price
62.67USD
Spread / Average Target
+55.54%

Quarterly revenue - Rate of surprise